The Institute for Quality and Efficiency in Health Care (IQWiG) was commissioned by the Federal Joint Committee (G-BA) to ...

Covid vaccine maker Moderna plans to sextuple the number of products it has approved over the next three years, the company ...

A recent analysis investigated the state of metabolic disruption experienced by patients with spinal muscular atrophy (SMA), ...

Moderna should not be left off the list of interesting investment opportunities, as the company has one of the best pipelines ...

DBS analyst Mark Kong CFA has maintained their bullish stance on MRNA stock, giving a Buy rating yesterday. Mark Kong CFA has given his Buy ...

In an effort to build its commercial capacity, Moderna on Thursday announced it is lowering research and development spending ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...

Moderna said the changes will reduce the cumulative spend on R&D between 2025 and 2028 to $16 billion from $20 billion, and ...

Milan, Italy, 12 September 2024 – Genespire, a biotechnology company developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases, today announces the appointment of ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...

In the prioritized portfolio, the Company's rare disease candidates include therapies targeting two organic acidemias caused by deficient metabolic enzymes, methylmalonic acidemia (MMA ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID combination vaccine for approval in 2024Announces positive ...